Intrigued by the notion that morphologically normal cells are resisting the effects of paclitaxel, we searched the literature for other genes upregulated in these cells and found that many of them, including PRMT1 (Cho et al, 2012), ENO1 (Georges et al, 2011), STMN1 (Alli et al, 2007), LDHA (Zhou et al, 2010), ANXA5 (Di Michele et al, 2009), and HSPA8 (Sugimura et al, 2004), are associated with paclitaxel resistance in diverse cancers. This evidence concerns the gene PRMT1 and cancer.